Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

29.86 -0.10 (-0.33%)

Streaming Delayed Price Updated: 10:22 AM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Earnings Scheduled For August 14, 2023 ↗

August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Via Benzinga

2 Magnificient Growth Stocks I'm Buying in August ↗

August 02, 2023

These biotech stocks could markedly outperform the broader market.

Via The Motley Fool

3 Biotech Stocks That Analysts Are Drooling Over ↗

August 07, 2023

With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time.

Via InvestorPlace

Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023

August 03, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Announces Redemption of Outstanding Warrants

August 02, 2023

From Roivant Sciences

Via GlobeNewswire

Vivek 'Da Vek' Ramaswamy: The 2024 Presidential Candidate Who Might Just Rap His Inauguration Speech ↗

July 28, 2023

Donald Trump and Ron DeSantis have been the runaway favorites for the GOP nomination in the 2024 election, but there’s one candidate that has been climbing up the polls and gaining support from...

Via Benzinga

Roivant Sciences's Return on Invested Capital Insights ↗

June 29, 2023

Via Benzinga

Analyst Expectations for Roivant Sciences's Future ↗

June 29, 2023

Via Benzinga

Why Shares of Roivant Sciences Rose Wednesday ↗

June 28, 2023

The pharmaceutical company released fourth-quarter earnings.

Via The Motley Fool

Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease

July 27, 2023

From Roivant Sciences

Via GlobeNewswire

3 Biotech Stocks for Getting Rich in 2023 ↗

July 18, 2023

These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist.

Via InvestorPlace

2 Nasdaq Stocks That Could Soar This Week ↗

July 16, 2023

BridgeBio Pharma and Roivant Sciences could make big moves this week.

Via The Motley Fool

Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories ↗

July 14, 2023

Benzinga

Via Benzinga

Why Roivant Sciences Stock is Trading Higher Today ↗

June 22, 2023

Roivant Sciences Ltd (NASDAQ: ROIV) released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with

Via Benzinga

A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout ↗

June 22, 2023

The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis.

Via Investor's Business Daily

Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover ↗

July 14, 2023

The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed.

Via Investor's Business Daily

Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗

July 14, 2023

Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)

Via Benzinga

Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program

July 11, 2023

Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others

From Roivant Sciences

Via GlobeNewswire

Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗

June 29, 2023

Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market...

Via Benzinga

5 Analysts Have This to Say About Roivant Sciences ↗

June 08, 2023

Via Benzinga

UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

June 28, 2023

From Roivant Sciences

Via GlobeNewswire

Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness' ↗

June 28, 2023

Via Benzinga

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

June 28, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023

June 26, 2023

From Roivant Sciences

Via GlobeNewswire

Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 22, 2023

Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private...

Via Benzinga

Why Roivant Sciences Stock Is Perking Up Today ↗

June 22, 2023

Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock.

Via The Motley Fool

Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday ↗

June 22, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period

June 22, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis

June 21, 2023

From Roivant Sciences

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023 ↗

June 08, 2023

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.